Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Trial ID or NCT#
This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study
- - >/= 18 years-old - Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or - Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers - >/= 6 months from the date of CAR-T infusion - Fluent in English - Able to attend and participate in in-person testing (Arm I) - Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II)
- - Concurrent enrollment in a CAR-T therapeutics research study - Unable to be present for the scheduled testing - Unable to participate in testing due to severe cognitive or physical limitation - Actively receiving chemotherapy - Progressive cancer
Contact us to find out if this trial is right for you.
Brian J Scott, MD